The introduction of the aromatase inhibitors made a monumental leap in the field of breast cancer therapy and clinical trials have demonstrated the superiority of letrozole over tamoxifen in first-line endocrine therapy in postmenopausal women with advanced hormone receptor positive breast cancer [35]. This evidence concerns the gene NR4A1 and breast carcinoma.